Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations

K Ragupathy; M Ferguson

doi:10.3109/01443615.2010.539719

Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations

J Obstet Gynaecol. 2011;31(2):178-9. doi: 10.3109/01443615.2010.539719.

Authors

K Ragupathy¹, M Ferguson

Affiliation

¹ Department of Oncology, Ninewells Hospital, Dundee, UK.

PMID: 21281038
DOI: 10.3109/01443615.2010.539719

Abstract

Our study adds to the BRCAness theory that hereditary ovarian cancers with BRCA 1 or 2 mutations show better chemosensitivity when compared with sporadic ovarian cancers.

MeSH terms

Antineoplastic Agents / therapeutic use*
Doxorubicin / therapeutic use
Female
Genes, BRCA1*
Genes, BRCA2*
Humans
Ifosfamide / therapeutic use
Middle Aged
Mutation
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / genetics*
Ovarian Neoplasms / mortality
Platinum Compounds / therapeutic use*
Survival Rate

Substances

Antineoplastic Agents
Platinum Compounds
Doxorubicin
Ifosfamide